Objective: The experience with the Carbomedics (CM) and the St. Jude Medical (SJM) bilea¯et mechanical prostheses was evaluated to determine thromboembolic and hemorrhagic complications and predictive risk factors. Methods: From 1989 to 1994, a total of 625 patients had mitral valve replacement (CM, 240; SJM, 385); 32.5% (203), concomitant procedures and 32.8% (205), previous cardiac surgery, primarily valve replacement procedures. Results: The pre-operative variables did not distinguish the populations, except for previous surgery CM 37.9% and SJM 29.6% (P , 0:05). The pre-operative variables (type of prostheses, cardiac rhythm, coronary artery bypass, NYHA III/ IV, advancing age, gender, urgency status and previous surgery) were not predictive of overall thromboembolism (TE), major TE, minor TE, prosthesis thrombosis and hemorrhage (P not signi®cant; P NS). The linearized rate of total TE events for overall MVR was 5.0%/patientyear (CM 4.4; SJM 5.4). The # 30 day major crude rate was 0.44%, while the . 30 day late major event rate was 2.0%/patient-year. Of the total TE events 91% of # 30 days and 75%, . 30 days had an INR , 2.5 at or immediately prior to the event. The thrombosis rate (included in TE events) was 0.63%/patient-year (ten events, four managed successfully with thrombolysis, ®ve successfully with reoperation, and one fatality identi®ed at autopsy). The freedom, at 5 years, from major/fatal TE, thrombosis and hemorrhage from anticoagulation was 88.2%, and 89.5% exclusive of early events. Conclusions: This non-randomized prospective observational evaluation of the CarboMedics and St. Jude Medical prostheses has not revealed any differentiation in performance of the prostheses. The study serves as a single institution experience with the potential for future comparative evaluation. q
Introduction
There has been a choice of mechanical prostheses and bioprostheses as valvular substitutes for cardiac valve replacement surgery for 25 years. The ®rst mechanical prosthesis, the Starr±Edwards caged-ball valve (Baxter Healthcare Irvine, CA) was introduced 37 years ago. The developments in mechanical prostheses have been monolea¯et and bileaflet designs, both formulated with pyrolytic carbon in whole or in part. The developments over the past two decades have been introduced to reduce or eliminate valve-related complications, namely thromboembolism and thrombosis, anticoagulant-related hemorrhage and structural failure, as well as to optimize hemodynamic performance [1±29] Jude Medical prosthesis has pyrolytic carbon over graphite substrate for both housing and lea¯ets. The lea¯ets are¯at and impregnated with tungsten for radiopacity in special three-axis radiographic views. The CarboMedics, on the other hand, has a solid Pyrolite w carbon housing and¯at lea¯ets of Pyrolite w carbon coated over tungsten loaded graphite substrate. The prosthesis has excellent radiopacity with the radiopaque titanium stiffening ring and increased tungsten content of the lea¯et substrate.
The lea¯ets of the St. Jude Medical prosthesis are ori®ce oriented and closing forces are supported by the pivot system. The pivot ears are raised above the housing and lea¯et motion is by rotation. The CarboMedics prosthesis, on the other hand, has the lea¯et pivot retention mechanism within the housing without pivot guards, struts or ori®ce projections. Lea¯et motion with the CarboMedics prosthesis is also by rotation.
The CarboMedics prosthesis has a titanium stiffening ring which prevents deformation of the valve ori®ce but facilitates rotation of the valve within the sewing ring. The St. Jude Medical prosthesis which as originally introduced was not rotatable. The newly introduced St. Jude Medical Masters series is rotatable but was not utilized in this study interval. For the small aortic annulus both prostheses manufacturers have introduced special versions to support optimization of hemodynamics±the St. Jude Medical Hemdynamic Plus (HP) and the CarboMedics TopHat prostheses. Both of these prostheses are designed with minimization of the external valve diameter.
Patient population
From September 1989, the time of commencement of the University of British Columbia in the United States -Food and Drug Administration CarboMedics investigational study, to June 1994 the CarboMedics (CM) and St. Jude Medical (SJM) prostheses were evaluated in a non-randomized prospective study. The prosthesis selection was at the discretion of the surgeon.
Mitral valve replacements were performed in 625 patients (male, 257; female, 368). The mean age of the population was 58:5^12:1 (SD) years (range 22±82 years). There were 54.7% NYHA Class III and 22.7% Class IV patients. Of the 625 patients, 317 (59.4%) were in atrial ®brillation preoperatively. The mean follow-up was 2:52^1:57 (SD) years, a total of 1576.3 years. The completeness of followup was 99.0%.
Concomitant procedures were performed in 32.5% (203) of the patients, coronary artery bypass in 22.9% (143) of the patients. Of the total population, 32.8% (205) had previous cardiac procedures, primarily valve replacement procedures. There was a preponderance of patients with previous operations in the CM group (37.9% versus 29.6% for SJM) (P , 0:05) ( Table 1 ). The patient populations for MVR for the CM and SJM groups were otherwise essentially the same considering the incidence of coronary artery bypass, atrial ®brillation, concomitant procedures, valve pathology and status of procedures (P NS).
The CM was implanted in 240 patients (male, 91; female, 149) and the SJM in 385 patients (male, 166; female, 219) in mitral valve replacements (MVR). The mean age of the MVR-CM population was 59:8^11:8 (SD) years (range 24±82 years) and of the SJM population, 57:7^12:2 (SD) years (range 22±81 years) (P NS). The MVR-CM patients were 56.3% NYHA class III and 22.5% class IV, while for SJM patients, 53.8% and 22.9%, respectively (P NS). The mean follow-up for the MVR-CM was 2:64^1:54 (SD) years (total 535.1 years) and for SJM was 2:45^1:59 (SD) years (total 925.6 years). The completeness of follow-up was 99.2% and 99.0%, respectively. 
Methods and statistical analysis
The`Guidelines for Reporting Morbidity and Mortality after Cardiac Valvular Operations' were used for de®nitions of valve-related complications, categorization and statistical methods [30] . The recommended de®nitions of thromboembolic and hemorrhagic events proposed by Bodnar et al. [31] in the article entitled`Proposal for Reporting Thrombosis, Embolism and Bleeding after Heart Replacement ' have been incorporated in the evaluation. The thromboembolic and hemorrhagic complications have been categorized by these authors, as follows: The information on valve-related complications for this study was obtained by direct contact with patients, family physicians, consultants, hospital health records, and of®cial death registries over a closing interval of 6 months in 1995.
The valve-related complications and composite indexes of these valve-related complications were evaluated in the time-related manner by actuarial life-table techniques (Cutler±Ederer method). The Wilcoxon±Gehan statistic was used to provide comparison of complication-free curves. Linearized occurrence rates (events per 100 patient-years or percent per patient-year) were utilized speci®cally for documenting thromboembolic and hemorrhagic complications. Overall thromboembolic and hemorrhagic rates encompass early events (#30 days) and late events (.30 days). Late events are expressed separately from the overall events. Hazard function evaluations are demonstrated for thromboembolic and hemorrhagic complications, and valve-related mortality and reoperation for the overall population groups. The predictors of early mortality were determined by logistic regression and the predictors of late mortality and thromboembolism by the Cox proportional hazard regression model (SPSS statistical package V6.1). The parameters evaluated were prosthesis types, cardiac rhythm, coronary artery bypass surgery, NYHA III/IV, advancing age, gender, urgency status and previous valvular surgery. The hazard functions for thromboembolism, thromboembolism and hemorrhage, reoperation and valve-related mortality are expressed at intervals of 6 months.
Results
The early mortality for the total population of mitral valve replacements was 6.7% (42 events) (CM, 5.4%; SJM, 7.5%). There were two (4.8%) valve-related deaths while cardiac causes were 40.5% (17) and non-cardiac causes and surgical causes were 55% (23) . The risk factors of early mortality were NYHA III/IV (odds ratio 3.5, P 0:0002) and previous cardiac procedures (odds ratio 4.6, P 0:033).
The overall mortality and mortality from valve-related complications are detailed in Table 2 for the overall population (including the 95% con®dence limits) and by the prosthesis types.
The mortality (early and late valve-related) for the overall 
a Mortality and mortality from valve-related complications-mitral valve replacement. patient population was 3.0%/patient-year (47) (CM 2.8 and SJM 3.1%/patient-year). The valve-related rate of late mortality was 0.63%/patient-year. There were three deaths due to major thromboembolism, one due to prosthesis thrombosis and four due to hemorrhage. The risk factors of late mortality were male gender (odds ratio 2.00, CL 1.1±3.6, P 0:02), previous cardiac operations (odds ratio 3.32, CL 0.99±11.08, P 0:05) and NYHA III/IV (odds ratio 1.98, CL 1.05±3.73, P 0:03). The patient survival, at 5 years, was 79:9^2:5%. The valve-related complications are summarized in Table  3 for overall mitral valve replacement and by prosthesis types (CM and SJM). The freedom from valve-related mortality, excluding early mortality and sudden unexpected deaths was, at 5 years, 97:9^0:7%.
The experience from valve-related reoperations for MVR is shown in Table 4 . There were two fatalities from 21 reoperations, reoperative mortality 9.5%. The freedom from reoperation for the overall population was 97:5^0:8% at 3 years and 91:8^2:4% at 5 years.
The major consideration of this clinical report is the assessment of thromboembolic complications. Tables 3  and 4 detail thromboembolic and hemorrhagic complications for the overall MVR population but also by the prosthesis-types (CM and SJM). The incidence of total thromboembolic events was 5.0%/patient-year, a total of 79 events (Table 3 ). The linearized rate for minor events was 2.5%/patient-year (40) and for major events including thrombosis was 2.5%/patient-year (39) . There were ten thrombotic events or 0.6%/patient-year. There were no risk factors, inclusive of prosthesis-types and cardiac rhythm, of thromboembolic events, whether considered for overall, major, minor or thrombosis and overall with exclusion of early events (P NS).
The thromboembolic events and major anticoagulant complications have been considered for two time intervals, #30 days and .30 days ( Table 5 ). The overall major events (.30 days) (major, reversible, thrombosis and fatal) was 2.0%/patient-year. The linearized rate of overall hemorrhage was 1.5%/patient-year. Of the 625 patients the number of major events .30 days were two major TE reversible, 18 major TE permanent, three systemic TE major, nine thrombosed prostheses and of the total, three fatalities. There were 23 overall hemorrhagic events with four fatalities requiring hospitalization or outpatient blood transfusions. There were, within the hospital or early period #30 days, six major thromboembolic events, a rate of 1.0%, with one fatality, 0.2%, and one non-fatal thrombosis event, 0.2%. The early hemorrhagic rate (non-fatal) was also 0.2%, one event.
Figs. 1 and 2 illustrate the freedom for MVR of thromboembolic and hemorrhagic events overall and exclusive of early events (#30 days). The ®gures show the freedoms from major thromboembolism, and overall major/fatal thromboembolism, thrombosis and hemorrhagic events. The freedom from major thromboembolism was, at 5 years, 91:5^1:8% and 92:7^1:7% with exclusion of early events (Fig. 1) . The freedom from thrombosis was, at 5 years, 96:2^1:5% and 96:4^1:5% with exclusion of early events. The assessment of overall thromboembolic and hemorrhagic events (Fig. 2 ) revealed 5 year freedom of 88:2^1:9% and 89:5^1:9% with exclusion of early events.
The hazard rates of overall thromboembolic and hemorrhagic events are demonstrated in Fig. 3 . The hazard rates of valve-related mortality and reoperation, including mortality from reoperation are illustrated in Fig. 4 .
The anticoagulant status of patients who experienced thromboembolic events at the various time intervals was determined. The four thromboembolic events in hospital with MVR were all anticoagulated at an INR of ,2.5 at or immediately prior to the event. There were 75 MVR post-hospital events and 76% were inadequately anticoagulated. Of the 79 events, 11 events occurred in the time period #30 days and 91% had an INR ,2.5. There were 68 events occurring at .30 days and 75% had an INR ,2.5. The rhythm at the time of the events was atrial ®brillation, 33% and normal sinus rhythm, 67%.
There were ten episodes (CM, 6; SJM, 4) of prosthesis thrombosis, 0.63%/patient-year (Table 3 and 5). All these patients occurred out of hospital with one within 30 days of operation. Four patients were managed successfully with thrombolytic therapy and ®ve patients were managed successfully with reoperation. There was one fatality related to thrombosis diagnosed at autopsy. This patient died one year following fourth cardiac surgical procedure and third mitral valve replacement. The patient was in atrial ®brilla-tion and adequately anticoagulated. There were four cases managed successfully with thrombolytic therapy with one minor thromboembolic event. There were ®ve cases managed successfully with reoperation; all had prosthesis replacement. The one case of thrombosis that occurred early after discharge was managed initially with thrombolytic therapy but developed cardiac tamponade and required reoperation. The thrombosis had resolved at surgery but the prosthesis was replaced. Of the ten combined SJM and CM thrombotic cases, nine had an INR of less than 2.5. One SJM case was adequately anticoagulated at the time of the event. Of the mitral valve replacements who had thromboembolic events with an INR , 2.5, 33% were in atrial ®brillation and 67% were in normal sinus rhythm.
Discussion
The major valve-related complications of mechanical prostheses have been anticoagulant hemorrhage, thromboembolism, including thrombosis, and structural failure. purpose of this documentation is to report the experience of the performance of the two predominant bilea¯et mechanical prostheses, St. Jude Medical and CarboMedics, in mitral valve replacements. The University of British Columbia commenced utilization of the CarboMedics prosthesis in September 1989 as part of the multicentre investigational study [13, 24] . The experience with the CarboMedics and St. Jude Medical prostheses between September 1989 and June 1994 inclusive formulate the patient population of this study. The study is an observational evaluation of the two prostheses.
Mechanical prostheses have been utilized for over 35 years as substitutes for diseased native valves. The successful mechanical prostheses have been the Starr±Edwards caged ball prosthesis and various monolea¯et and bilea¯et mechanical prostheses. The question over the past 3 decades has been to provide prostheses with the potential for reduction in thromboembolic phenomena and the related complication of anticoagulant or antithromboembolic hemorrhage. The literature has not provided appropriate evaluation to determine the bene®cial effect of advancements in prostheses design [1,7,9,13,16,19,24,26±29] . There have been only two randomized trials, of signi®cance, both comparing the performance of the St. Jude Medical bilea¯et prosthesis to the Medtronic±Hall (Medtronic Inc., Minneapolis, MN) monolea¯et prosthesis [2, 4] . The current knowledge has been derived primarily from recent reports on the clinical performance of individual prostheses [1±29]. The major concern with these reports has been the wide variation of reported results on thromboembolic events. There remains extensive inconsistency of clari®cation of de®nition for most reports do not differentiate between major and minor events and do not indicate the standard of reporting. For mitral valve replacement with mechanical prostheses the incidence of thromboembolic rates have ranged between 0.3 and 6.6%/patient-year [1,8,9±11,13,16,20,22,24] . Smith and coauthors [11] have reported the incidence of thromboembolic events to be 0.3%/patient-year for mitral valve replacement for the St. Jude Medical prosthesis. On the other hand, Horstkotte and colleagues [9] have reported unexpected ®ndings with the St. Jude Medical prosthesis with an incidence of 5.1%/patient-year for mitral replacements. These authors when considering only ®rst or most serious of several events, documented incidence of 4.1%/ patient-year, for mitral valve replacement. Ibrahim et al. [16] have also reported high total thromboembolic rates with the St. Jude Medical prosthesis, 4.4%/patient-year for mitral valve replacements. Several reports document only events that occur beyond the early 30 day interval and consequently provide an unfair assessment of patient morbidity and mortality [9, 13, 14, 17, 23, 24] . Jegaden and investigators [18] , on the other hand, have expressed concern over the occurrence of major thromboembolism during the early postoperative period, often when anticoagulation has yet to be adequately controlled. There is also limited information provided on the level of anticoagulation at the time of both thromboembolic and hemorrhagic events. The extent of patient follow-up and depth of evaluation, as well as, the adequacy of anticoagulation management are likely contributing factors to the wide range of reported events.
This report attempts to alleviate some of these concerns by reporting total overall events, events occurring ,30 days, events occurring $30 days and classifying events as major (reversible and permanent), minor, fatal and thrombotic occlusion. The study has documented the adequacy of anticoagulation at the time of event occurrence. An INR level of 2.5 was considered as the minimal level of adequacy of anticoagulant management. The study did not determine the anticoagulant status of patients who did not have a thromboembolic event, or at times remote of an event.
The in¯uence of anticoagulant management on hospital and post-hospital, and #30 days and .30 days thromboembolism has been reported in mitral and multiple valve replacements with the mechanical prostheses populations by Jamieson and collaborators [32] .
The overall thromboembolic rate, considering both major and minor events, for mitral replacements was 5.5%/patientyear. These results are comparable to the reported results by Horstkotte et al. [9] and Ibrahim et al. [16] with the St. Jude Medical prosthesis. These results are at variance to the literature for the St. Jude Medical prosthesis, the range from other reports to be 0.6±2.5%/patient-year for mitral replacements [10, 11, 19, 20] . The results with the CarboMedics prosthesis are 0.6±2.27%/patient-year for mitral replacements [8, 13, 22] .
The series documenting comparative studies have also showed varying results [2, 4, 21] . Aramendi et al. [3] compared thromboembolic rates in the mitral position, 5.23%/patient-year for the St. Jude Medical prosthesis and 5.62%/patient-year for the Bjo Èrk±Shiley prosthesis. The thromboembolic rates for other monolea¯et prostheses have also been extensively varied [1, 2, 7, 11, 29, 33] . Fiori et al. [4] , reporting on a randomized trial for mitral replacements identi®ed the St. Jude Medical prosthesis rate to be 1.6%/patient-year and the Medtronic-Hall prosthesis rate to be 4.9%/patient-year. Butchart and colleagues [33] reported the mitral Medtronic Hall rate to be 3.0%/patient-year while Kim et al. [21] reported 0.8%/patient-year for mitral Medtronic-Hall implantations. Kim and coauthors [21] also reported on the Bjo Èrk±Shiley Monostrut prosthesis (Alliance Medical Technology, Irvine, CA), 3.0%/patientyear for mitral replacements. Orszulak and colleagues [6] reported a mitral rate of 4.6%/patient-year with Bjo Èrk± Shiley standard and convex-concave prostheses. This wide ranging reporting of thromboembolic rates must be related to the detailed nature of evaluation and possibly the extent of anticoagulation.
The most important aspect of thromboembolism is the rates of major events, as well as hemorrhagic events. The major event rate in the present series of combined St. Jude Medical and CarboMedics prostheses is 2.47%/patient-year for mitral replacements. The $30 day event rates was 2.0%/ patient-year. The reports by Horstkotte and Ibrahim and colleagues [9, 15] range from 1.2±1.4%/patient-year for mitral replacements. The incidence of anticoagulant hemorrhage in these reports have shown less variation. The major hemorrhagic rate in the authors combined series is 1.5%/ patient-year for mitral valve replacements. The hemorrhagic rates for the series of St. Jude Medical prosthesis by Horstkotte and Ibrahim and colleagues [9, 15] range from 1.8± 2.8%/patient-year for mitral replacements. These apparent differences may explain the higher major event rates in the authors series. The inadequacy of anticoagulation in our series of overall thromboembolic events may also be a contributing factor; 91%, and 75% for mitral replacements ,30 days and $30 days, respectively.
The prostheses thrombosis rates for our combined series was 0.63%/patient-year for mitral replacements. The thrombosis rate reported by Orszulak and coauthors [6] for Bjo Èrk± Shiley standard and concave-convex prostheses was 0.27%/ patient-year. Aagaard et al. [22] and Fiane et al. [27] reported a CarboMedics rate of 0.3%/patient-year. NitterHauge et al. [1] documented the thrombosis rate for the Medtronic-Hall monolea¯et prosthesis at 0.1%/patientyear for mitral implants. The rate of prosthesis thrombosis with the St. Jude Medical and the Bjo Èrk±Shiley Monostrut has been reported as low [4,10±12,16,18±20] In the authors series of the ten mitral events, ®ve were managed successfully with thrombolysis and ®ve with reoperation. There was a fatality identi®ed at autopsy. Of the total ten thrombosed prostheses, nine had INR levels of less than 2.5 at or immediately prior to the event. There were no independent predictors of prosthesis thrombosis including prosthesistype, thus documenting no difference in propensity to thrombosis with the CarboMedics and St. Jude Medical prostheses.
The fatality rate from thromboembolism has been infrequently reported. The rate in the authors combined series was 0.13%/patient-year for mitral replacements. The reported fatality rates for mitral prostheses is 0.09±0.5%/ patient-year [10±12, 16, 20] .
Sudden unexpected death has been considered to be a valve-related mortality [30, 34] . In our series the incidence of sudden unexpected death was 0.06%/patient-year for mitral valve replacement. The incidence of sudden death with the St. Jude Medical prosthesis ranges from 0.06± 0.9%/patient-year for mitral replacement except the series reported by Fiori et al. [4] , 2.5%/patient-year for mitral valve replacement [10, 12, 18, 20] . Rooney and colleagues [35] studied sudden expected deaths in a large series with the Medtronic-Hall prosthesis. A total of 69 deaths were considered sudden or unwitnessed, 70% were submitted to autopsy and 90% of the deaths were non-prosthetic in origin. In our series unexpected deaths were not considered sudden deaths if there was documented coronary artery disease or known history of angina. Butchart [34] reported in an editorial on the Rooney publication that it was illogical to attribute all sudden deaths to the prosthesis in the absence of an autopsy.
The management and results of dealing with thrombosed mechanical prostheses have received limited attention [35± 41]. In our series there were ten thrombosed prostheses and ®ve were subjected to reoperation. Deviri and coauthors [36] reported on mortality of surgical management of obstructed mechanical prostheses, namely Bjo Èrk±Shiley, Medtronic-Hall and St. Jude Medical. The mortality of prosthesis replacement was 12% and prosthesis declotting, 13%. Martinelli and co-investigators [39] , in 1991, evaluated 72 thrombosed obstructions of 3637 patients. The overall mortality was 25% with reoperative mortality of 17%, of 62 patients. Of 57 reoperations, valve re-replacement was performed in 37 and debridement in 27. Re-thrombosis rate was 41% of debrided prostheses. Roudaut et al. [42] reported in 1992 on thrombolytic management of 64 patients with 75 episodes of thrombosis. The success rate was 75% (55), while of 18 failures nine came to emergency surgical management. There were nine overall deaths, four due to cerebrovascular accident, four due to cardiac arrest and one due to hemorrhage. There were 11 cases of embolism, four cerebral resulting in death. The event-free success was 63% with mitral prostheses while 85% with aortic prostheses. In the authors series four cases were treated successfully with thrombolysis for mitral prosthesis thrombosis with one minor thromboembolic event. There always is an embolic risk with thrombolysis. Thrombolysis is likely to be successful if the thrombus is of recent origin and there is no pannus formation. It appears that operation for prosthesis thrombosis should be accompanied with re-replacement and not with thrombus removal.
The appropriate anticoagulant management of mechanical prosthesis is unresolved [43±47]. The goal of therapy is to minimize hemorrhagic complications without an increase of thromboembolic events. The recommended range of anticoagulation for patients with mechanical prostheses-INR 3.0±4.5 has been challenged by several studies [43, 44, 46, 48] . Saour et al. [46] compared low dose versus high dose warfarin anticoagulation and found high level of anticoagulation was associated with increased bleeding but no decrease in the rate of systemic embolism. Altman et al. [44] observed the same results comparing INR 2.0±3.0 with 3.0±4.5 with salicylate acid and dipyridamole. Skudicky et al. [43] found that low dose anticoagulation (INR 2.0±2.5) combined with dipyridamole 300 mg/day systemic embolism and valve obstruction was low and little attention to INR was safe.
Butchart and colleagues [49] made a major contribution by recommending anticoagulation to prosthesis thrombogenicity and patient risk factors. These authors compared low anticoagulation (mean INR 2.5) with moderate anticoagulation (mean INR 3.0) and identi®ed that in the MVR group with the low group was 80% free of all events and 93% free of serious events at 3 years compared to 89% and 98%, respectively, in the moderate group. This study was conducted with the Medtronic±Hall prosthesis and recommended INR of 3.0 for MVR. Turpie and colleagues [47] studied mechanical prostheses and tissue prostheses plus atrial ®brillation or history of thromboembolism with high 3.0±4.5 INR randomized to salicylatic acid (100 mg/day) with no differentiation to valve position. Major hemorrhagic events in this well controlled randomized study revealed a hemorrhagic rate of 8.5%/patient-year for the aspirin group and 6.6%/patient-year for the placebo group. The authors emphasized major systemic embolism, nonfatal intracranial hemorrhage, death due to hemorrhage or death due to vascular causes with respective rates of 3.9%/patient-year and 9.9%/patient-year but major systemic embolism 1.6%/ patient-year and 4.6%/patient-year. The authors concluded that the low increase in bleeding was offset by considerable bene®t. One must be critical of this study for unacceptable hemorrhagic rates while identifying some bene®t against embolism from Aspirin. As indicated by the authors, a less intense anticoagulation regimen should provide a reduction in major bleeding.
Meschengieser and co-authors [50] reported, in 1997, the results of a randomized trial with mechanical prostheses undifferentiated by position. The patients were randomized to INR 2.5±3.5 plus salicylatic acid 100/mg/day or INR 3.5± 4.5. The thromboembolic rate was 1.32%/patient-year for the low-intensity 1 ASA group compared to 1.48%/patientyear for the high intensity groups. The major hemorrhage rates were 1.13%/patient-year and 2.33%/patient-year, respectively. There was one thrombotic case in the low intensity group but no increase in gastrointestinal hemorrhage. The patient population in this study was primarily Starr±Edwards cage-ball and monolea¯et prostheses.
Butchart et al. [49] acknowledged the in¯uence of atrial ®brillation in mitral disease or alone. Atrial ®brillation without valvular heart disease has a rate in excess of 5%/patientyear and falling to 1.5±3.0%/year with anticoagulation [51± 53]. The recommended INR of 3.0 for MVR requires some adjustments for stroke risk factors.
The authors study could not identify any in¯uence of prosthesis type on overall, major or minor thromboembolism and thrombosis. The late major TE rates were high (2.0%/patient-year for mitral replacements) and higher including early events #30 days. The thrombosis rates were high, as well as in other reported series [11, 12, 16, 18, 20] . The commencement of anticoagulation, at our hospitals, on the 3rd to 4th day without heparinization may be less than optimal. The long-term management of anticoagulation by numerous family physicians and internists may require reconsideration and possibly home anticoagulation management [48, 54, 55] . Irrespective of these concerns, our results parallel the embolic rates con®rmed with the well conducted studies of Horstkotte et al. and Ibrahim and colleagues [9, 16] . The concluding comment is that mechanical bilea¯et prostheses, both CarboMedics and St. Jude Medical, in mitral replacement, carry a high risk of thromboembolic and hemorrhagic complications.
